Center for Medicine in the Public Interest Statement on ITC TRIPS Waiver Report

  • CMPI | by: CMPI |
  • 10/18/2023 12:00 AM
Center for Medicine in the Public Interest Statement on ITC TRIPS Waiver Report

Center for Medicine in the Public Interest Statement on ITC TRIPS Waiver Report
 
October 18, 2023, New York, NY. Yesterday, the U.S. International Trade Commission published its report on possible expansion of the TRIPS waiver on Covid-19 diagnostics and therapeutics. In response Center for Medicine in the Public Interest President and Co-Founder Peter Pitts issued the following statement:
 
"Now that the USITC has completed its investigation, it's time for the U.S. Trade Representative to make clear that the United States will not support an expanded TRIPS waiver -- and recommit the United States government to protecting American innovation at home and abroad.
 
"America led the world in developing Covid-19 vaccines and therapeutics because of our strong intellectual property protections. The world is now awash in vaccines, therapeutics, and diagnostics thanks to IP protections -- not despite them. 
 
"Expanding the TRIPS Waiver is unnecessary and would also undermine America's ability to respond to future pandemics."

 
Sign Up for Our Email Newsletter

RECENT NEWS

Drug shortages reaching record levels
  • Scripps News
  • 09/19/2023 12:00 AM

Drug shortages reaching record levels

Drug Shortages reaching record levels in the United States in nearly a decade...  Read more

Sorry, but the ‘drugs from Canada’ don’t work

Sorry, but the ‘drugs from Canada’ don’t work

“Drugs from Canada” is a policy that won’t work. And a political soundbite that won’t die....  Read more

When It Comes to FDA Communications

When It Comes to FDA Communications

Perhaps the most important lesson learned from the COVID-19 experience is that American health illiteracy kills....  Read more

DRUGWONKS BLOG